|
Gregory Bell, M.D.: Vice President of Clinical Research & Development and Chief Medical Officer.
Gregory Bell, M.D. serves as our Vice President of Clinical Research and Development and Chief Medical Officer. In this role Dr. Bell is responsible for the Company's development programs, clinical trials, regulatory operations and medical affairs. Dr. Bell has worked in academic medicine and the biopharmaceutical industry for over fifteen years with extensive experience in both basic and clinical research. Before joining KAI in August 2005, Dr. Bell served as Vice President of Clinical Development and Clinical Operations at Abgenix, Inc. where he was responsible for managing clinical operations and biometrics for all clinical programs and for leading the clinical development of product candidates in inflammatory and metabolic diseases. Prior to Abgenix, Dr. Bell held several positions at Merck & Co., Inc most recently as National Arthritis Medical Director in the Medical and Scientific Affairs department of the U.S. Human Health Division. Dr. Bell began his career at Merck as Program Manager in Merck Research Laboratories supporting the Cancidas® and Arcoxia® programs. Dr. Bell earned his medical degree from Cornell University Medical College and received further training in internal medicine and rheumatology at Brown University and the University of California, San Francisco. | 